What Are Liver Enzymes? Symptoms, Causes and Treatment of Elevated Levels

ContributorsProf. Dr. Mustafa ÖzdoğanAuthor · Medical review · Editorial approval

PublishedAug 23, 2022

UpdatedOct 20, 2026

26 min read

What Are Liver Enzymes? Symptoms, Causes and Treatment of Elevated Levels

In this article

My Liver Enzymes Are High: What Does That Mean?

Elevated AST, ALT or GGT on blood testing is very common: approximately 10% of adults have elevated liver enzymes. Yet fewer than 5% of these people have serious liver disease. An enzyme elevation is therefore often not an alarm, but a question mark. The real issue is knowing which questions need investigation.

Three things have changed in this article:

The disease name has changed. An international consensus in 2023 replaced the terms NAFLD/NASH with MASLD and MASH . This is more than a name change: diagnostic criteria have changed too.
The “normal” ALT threshold has changed. Laboratory upper limits such as 55 U/L do not represent the true upper limit in healthy people. The current guideline gives a healthy upper limit of 29-33 in men and 19-25 U/L in women.
Effective drugs have been approved for the first time. For advanced fatty liver disease, resmetirom (March 2024) and semaglutide (August 2025) received approval, for the first time in history.

It also covers a vital issue for oncology patients: hepatitis B screening before chemotherapy. With one in three adults in Turkey thought to have encountered hepatitis B, this screening must not be overlooked.

What Does Each Enzyme Show?

Enzyme	Where it is found	What elevation indicates
ALT (alanine aminotransferase)	Mainly the liver	The enzyme most specific to the liver. Elevation indicates liver cell injury.
AST (aspartate aminotransferase)	Liver, heart, skeletal muscle, kidneys, red blood cells	May come from outside the liver. Elevated AST alone does not mean liver disease.
ALP (alkaline phosphatase)	Bile ducts and bone	Obstructed bile flow (cholestasis) or bone disease
GGT (gamma-glutamyl transferase)	Liver and biliary tract	Low specificity on its own. Its main role is to confirm that elevated ALP comes from the liver.

These are not actually “function tests.” The common term “liver function tests” is misleading: AST, ALT, ALP and GGT do not show how well the liver works , but whether it is injured . True indicators of liver function are albumin, bilirubin and INR (clotting time). This distinction is important in practice: enzymes may be normal or even low in advanced cirrhosis because few cells remain to be injured.

The Question of a “Normal Value”

A laboratory’s reference range is derived from the distribution of people tested there. This population includes people with fatty liver, excess weight and hepatitis. Consequently, the reference upper limit exceeds the upper limit for a healthy person.

	Typical laboratory range	True healthy upper limit (ACG 2017)
ALT—men	~7-55 U/L	29-33 U/L
ALT—women	~7-55 U/L	19-25 U/L
AST	~8-48 U/L	Similarly lower
ALP	~40-129 U/L	Varies with age, pregnancy and bone status
GGT	~8-61 U/L	Very sensitive to alcohol and medications

Practical meaning: A woman with ALT of 45 U/L may see “normal” on her laboratory report, even though this is almost twice the expected healthy upper limit for a woman. A “borderline normal” ALT merits investigation, particularly with metabolic risks such as excess weight, diabetes or high triglycerides. This does not mean everyone should panic; first ask whether the elevation is persistent.

How High, and How Serious?

Level	Multiple of the upper limit of normal	Interpretation
Borderline	< 2-fold	Very common; repeat measurement and risk assessment
Mild	2-5-fold	Fatty liver, alcohol, medications, chronic viral hepatitis
Moderate	5-15-fold	Acute hepatitis also enters the differential
Severe	> 15-fold	Paracetamol toxicity, ischemic hepatitis (shock liver), acute viral hepatitis —urgent assessment
Massive	> 10,000 U/L	Emergency

Read the Pattern, Not Just One Enzyme

Enzymes should be interpreted together, not individually. The main clinical patterns are:

Pattern	More likely causes	First step
Predominant ALT and AST (hepatocellular)	Viral hepatitis, drugs/toxins, MASLD, autoimmune hepatitis	Viral serology, medication/herbal product history, metabolic assessment
ALT ≫ AST, more than 10-fold	Acute viral or toxic hepatitis	Urgent assessment, paracetamol history
AST/ALT ratio ≥ 2 + elevated GGT	Alcohol-related liver disease	Stop alcohol, nutritional support, ultrasound
Markedly elevated ALP and GGT together (cholestatic)	Gallstones, bile duct tumor, liver metastasis, PBC/PSC	Ultrasound, then MRCP or CT if needed
Isolated elevated ALP, normal GGT	Bone origin —bone metastasis, vitamin D deficiency, Paget disease, healing fracture	ALP isoenzyme, vitamin D, bone assessment
Isolated elevated GGT	Alcohol, medications (phenytoin, carbamazepine), fatty liver— often harmless	Does not require further investigation alone
Isolated elevated AST, normal ALT and CK	Muscle origin, or rarely macro-AST	CK and aldolase; investigate macro-AST in persistent unexplained elevation

About Isolated GGT Elevation: This is the finding most often causing unnecessary anxiety. The American College of Gastroenterology states clearly: “Because it is not specific to liver disease, GGT should not be used as a screening test when other liver tests are normal.” An isolated, nonprogressive GGT elevation rarely reflects serious liver disease and usually does not require specialist referral. GGT’s main role is to distinguish whether elevated ALP comes from liver or bone.

Macro-AST: an overlooked pitfall that can lead to biopsy. AST sometimes binds an antibody, usually IgG, forming a large complex. Because it clears slowly from the blood, AST is measured as persistently elevated . The pattern is easy to recognize: High AST, entirely normal ALT, normal GGT, ALP, bilirubin and CK, and a completely healthy patient. Diagnosis uses a blood polyethylene glycol precipitation test. It is harmless, requires no treatment and prevents unnecessary liver biopsy.

Causes

1. Fatty liver disease—and its 2023 name change

NAFLD and NASH are no longer used. In June 2023, a Delphi consensus involving several international societies completely changed the terminology. This was not only because “non-alcoholic” was considered exclusionary and stigmatizing: the new system defines disease by something present rather than absent : metabolic dysfunction.

New term	Meaning	Previous equivalent
SLD	Steatotic liver disease—umbrella term covering all causes of liver fat	—
MASLD	Metabolic dysfunction-associated steatotic liver disease	NAFLD
MASH	Metabolic dysfunction-associated steatohepatitis	NASH
MetALD	MASLD plus increased alcohol consumption— a new, important intermediate category	No previous equivalent
ALD	Alcohol-related liver disease	Unchanged

MASLD diagnosis requires fat in the liver and at least one of the following five metabolic criteria :

Body mass index ≥25 kg/m² or waist circumference >94 cm in men, >80 cm in women
Fasting blood glucose ≥100 mg/dL, or post-meal glucose ≥140 mg/dL, or HbA1c ≥5.7%, or a diagnosis/treatment of type 2 diabetes
Blood pressure ≥130/85 mmHg or antihypertensive medication
Triglycerides ≥150 mg/dL or lipid medication
HDL cholesterol ≤40 in men, ≤50 mg/dL in women or lipid medication

Weekly alcohol amount	Women	Men	Diagnosis
Low	< 140 g	< 210 g	MASLD
Moderate	140-350 g	210-420 g	MetALD
High	> 350 g	> 420 g	ALD

For perspective: 10 g of pure alcohol is approximately one standard drink—100 mL wine (12%), 250 mL beer (5%) or 30 mL rakı (45%). Thus, 21 standard drinks weekly mark the MASLD–MetALD threshold for men.

How Common Is Fatty Liver in Turkey? In the multicenter DAHUDER study published in 2025, among people with at least one metabolic risk factor, MASLD prevalence was 75.7% in 14,371 Turkish adults . It was 56.5% with a single risk factor, rising with all five factors to 83.4%. In the same group, 12% had a FIB-4 score indicating advanced fibrosis risk. Turkish general-population data suggest fatty liver prevalence of approximately 48%, or 63% among people with excess weight. MASLD is therefore unquestionably Turkey’s most common cause of elevated liver enzymes.

2. Other causes

Group	Causes
Viral	Hepatitis A, B, C, D and E; also EBV and CMV infections
Medications and toxins	Paracetamol (see below), some antibiotics (amoxicillin-clavulanate is the most frequently implicated prescription drug), antiepileptics, tuberculosis drugs, methotrexate, herbal products and dietary supplements
Autoimmune	Autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC)
Inherited	Hemochromatosis (iron accumulation), Wilson disease (copper), alpha-1 antitrypsin deficiency
Obstruction	Gallstones, bile duct stricture, tumor
Outside the liver	Muscle injury (intense exercise, myopathies, statin myopathy), thyroid disorders, celiac disease, hemolysis, congestion from heart failure, heart attack

Herbal products and supplements: a rapidly growing problem. In the US drug-induced liver injury registry, herbal and dietary supplements accounted for 7% in 2004-2005, rising over the following decade to more than 20% . A study published in 2024 in JAMA Network Open examined six potentially hepatotoxic botanicals: turmeric/curcumin, green tea extract, Garcinia cambogia, blue cohosh, red yeast rice and ashwagandha. Among US adults, 4.7% (approximately 15.6 million people) had used at least one within the past 30 days.

Two points matter: (1) The risk concerns concentrated extracts, not brewed green tea. (2) Bodybuilding supplements containing anabolic steroids are a classic cause of prolonged jaundice in young men. When giving your doctor a medication list, include products you consider “natural.”

Paracetamol: the actual numbers. The previous article referred only to “high-dose paracetamol.” More specifically, a single adult dose above 150 mg/kg (approximately 7.5-10 g) is considered toxic to the liver; serious injury occurs most often above 15 g . The current labeled limit is 3 g per day (the older commonly cited figure was 4 g). People with chronic liver disease, regular alcohol use, fasting or malnutrition may experience toxicity at lower doses , requiring a reduced daily dose. Nevertheless, in liver disease, paracetamol is safer than NSAIDs for pain relief —provided it is used at low doses.

Do Not Test Immediately After Exercise. Intense resistance training can markedly elevate AST and ALT. The increase peaks on days 3-4 and may take 7-12 days to normalize. The rule is simple: repeat an abnormal transaminase result after at least a week without heavy exercise . Otherwise, a healthy athlete may undergo unnecessary investigations.

Liver Enzymes in Oncology Patients

Elevated liver enzymes in a cancer patient require a different differential from those in a healthy person. The following topics were absent from our previous article.

1. Hepatitis B screening before chemotherapy—particularly critical in Turkey

Why Is It So Important? Immunosuppressive treatments can allow dormant hepatitis B virus to multiply again. This is called HBV reactivation and can cause liver failure, interrupted cancer treatment and death.

The figure that makes Turkey distinctive is this: As Turkey’s Hepatitis B Guideline states, “One in three people over 18 is infected with HBV or has had HBV infection.” HBsAg positivity is approximately 4% , while anti-HBc positivity, indicating previous infection, is approximately 30%. Thus, a large proportion of patients are HBsAg-negative but anti-HBc-positive —and this group is also at risk.

In practice: testing HBsAg alone is insufficient. The American Society of Clinical Oncology’s 2020 opinion recommends screening all patients scheduled for systemic cancer treatment rather than selecting only a high-risk group.

Step	What to do
1. Screening	Before starting treatment, test HBsAg + total anti-HBc + anti-HBs together
2. If positive	If HBsAg or anti-HBc is positive, measure HBV DNA .
3. Prophylaxis	Entecavir, tenofovir disoproxil or tenofovir alafenamide is started before or together with cancer treatment .
4. Duration	Continue after cancer treatment ends for at least 12 months. The Turkish guideline extends this to 2 years for anti-CD20 drugs such as rituximab .

Risk level	Drugs
High (>10%)	Rituximab, obinutuzumab, ofatumumab (high risk even in HBsAg-negative/anti-HBc-positive patients); anthracyclines (doxorubicin, epirubicin); ≥10 mg prednisone equivalent daily for ≥4 weeks; stem cell transplantation
Moderate (1-10%)	Low-dose corticosteroids, T-cell-directed agents, immune checkpoint inhibitors
Low (<1%)	Methotrexate, azathioprine, steroid courses shorter than one week

Prophylaxis reduces reactivation risk by approximately 82% . This is one of oncology’s highest-yield simple preventive measures.

Immune checkpoint inhibitors can cause immune-mediated liver inflammation. Its frequency varies greatly with the drug:

Immunotherapy-related hepatitis—all grades

Pooled clinical trial data

Ipilimumab + nivolumab

Up to ~20%

Ipilimumab 10 mg/kg

~14%

Anti-PD-L1 alone

0-6%

Anti-PD-1 alone

0-3%

Ipilimumab 3 mg/kg

~1.2%

Ipilimumab toxicity is dose-dependent: there is approximately a tenfold difference between 3 mg/kg and 10 mg/kg. Combination treatment is an order of magnitude riskier than anti-PD-1 alone.

Grade	AST/ALT	ASCO 2021 approach
1	Up to 3 times normal	Continue immunotherapy and monitor
2	3-5-fold	Hold the drug. If no improvement within 3-5 days, prednisone 0.5-1 mg/kg/day
3	5-20-fold	Stop the drug; start methylprednisolone 1-2 mg/kg/day immediately
4	More than 20-fold	Permanently discontinue immunotherapy; methylprednisolone 2 mg/kg/day

A critical—and disputed—detail. In steroid-unresponsive cases, mycophenolate mofetil is added. The ASCO guideline states that infliximab, widely used for immune-mediated colitis, is contraindicated with liver involvement because infliximab itself can cause hepatotoxicity. This is among oncology’s most frequently repeated teachings.

However, this view began to be questioned in 2024-2025: case series using infliximab for steroid-resistant immunotherapy hepatitis found no marked hepatotoxicity and reduced steroid exposure. The NCCN guideline contains no explicit prohibition. This should therefore be read as “the guideline avoids it, but the data are disputed” rather than a definitive prohibition.

3. Liver Injury From Chemotherapy and Targeted Drugs

Drug	Effect on the liver	Practical importance
Oxaliplatin	Sinusoidal obstruction syndrome (“blue liver”)—detected histologically in 10-61% of treated patients	Enzymes are usually normal or mildly elevated. The main clues are progressively falling platelets and splenic enlargement. This matters when limiting chemotherapy cycles before surgery for colorectal liver metastases.
Irinotecan	Chemotherapy-associated steatohepatitis —20.2% (4.4% without chemotherapy)	After liver metastasis surgery, it increased 90-day mortality from 1.6% to 14.7% . This finding changed surgical practice.
Regorafenib	AST elevation 58-65%, ALT 39-45%	FDA boxed warning: severe and sometimes fatal hepatotoxicity
Pazopanib	ALT elevation 46-53%	FDA boxed warning. During the first 4 months, at least every 4 weeks, check liver tests
Lapatinib	ALT/AST elevation 37-53%; severe elevation 2-6%	Carries an FDA hepatotoxicity warning. *HLA-DRB107:01** carriers have a severe elevation rate of 7.7% versus 0.5% in noncarriers.
Methotrexate	Traditionally, cumulative-dose-related fibrosis	Recent questions suggest this risk may have been overstated; risk is largely concentrated in patients with underlying MASLD

4. Liver Metastases and Enzyme Patterns

A tumor that has spread to the liver typically produces a cholestatic pattern : ALP and GGT rise disproportionately to ALT and AST , while bilirubin may remain normal until very advanced disease. In a cancer patient, isolated ALP-GGT elevation warrants imaging, not simply “let’s repeat it.” Abdominal ultrasound is first-line, followed by cross-sectional imaging if needed. If elevated ALP is not accompanied by elevated GGT, bone may be the source—and in a cancer patient this may mean bone metastasis .

5. Cancer Screening in Patients With Cirrhosis

Cirrhosis of any cause, including MASH cirrhosis, carries a liver cancer risk. The current recommendation is: Abdominal ultrasound and AFP every 6 months. This screening is recommended for all patients with cirrhosis and selected chronic hepatitis B carriers. In contrast, routine screening is not recommended for MASLD without cirrhosis.

The Real Question: Is Fibrosis Present?

Long-term liver disease outcomes depend not on enzyme levels but on the degree of fibrosis (scarring). Assessment has therefore shifted from “how high are the enzymes?” to “is there fibrosis?” Fortunately, this can often be determined without a biopsy .

First Step: FIB-4 Score

This free, widely applicable score uses only age, AST, ALT and platelet count in its calculation.

FIB-4	Interpretation	What to do
< 1.3	Low likelihood of advanced fibrosis	Primary care follow-up. With diabetes or at least two metabolic risk factors, repeat every 1-2 years; otherwise, every 2-3 years
1.3 - 2.67	Indeterminate	Elastography (FibroScan) or ELF test
> 2.67	High likelihood of advanced fibrosis	Hepatology assessment
Over age 65, the lower threshold is raised to 2.0. Under age 35, FIB-4 is unreliable; proceed directly to elastography.

Second Step: Elastography

FibroScan value (kPa)	Interpretation
< 8	Advanced fibrosis excluded
8 - 12	Indeterminate/possible fibrotic MASH
> 12	High likelihood of advanced fibrosis
≥ 20	Suggestive of cirrhosis

The CAP value measured by the same device indicates steatosis severity: 238-260 dB/m is mild, 260-290 moderate, and above 290 severe.

When Is Biopsy Needed? Biopsy is now not the first choice but the final step. Indications include diagnostic uncertainty, conflicting or indeterminate noninvasive tests, suspected autoimmune or drug-induced hepatitis, and unexplained transaminase elevation lasting more than six months.

Treatment

Treatment primarily addresses the cause: antivirals for viral hepatitis, phlebotomy for hemochromatosis, chelation for Wilson disease, and stopping the responsible drug. MASLD/MASH now has further options.

1. Weight Loss—Still the Strongest Intervention

Weight loss	Expected benefit
3-5%	Reduced liver fat
7-10%	Regression of inflammation (steatohepatitis)
10% or more	Fibrosis regression —the main goal

Accompanying core recommendations: Mediterranean-style diet, limiting sugar- and fructose-rich foods/drinks, at least 150 minutes of moderate aerobic exercise weekly, plus 2 days of resistance exercise per week. Exercise reduces liver fat even without weight loss .

2. Drug Treatment—For the First Time

Drug	Approval	Indication	Results (weeks 52-72)
Resmetirom (Rezdiffra)	FDA March 14, 2024; EU August 19, 2025	Noncirrhotic moderate-to-advanced fibrosis (F2-F3) MASH	MASH regression 25.9-29.9% (placebo 9.7%); fibrosis regression by at least one stage 24.2-25.9% (placebo 14.2%)
Semaglutide 2.4 mg (Wegovy)	FDA August 15, 2025; EU March 26, 2026	Noncirrhotic MASH with F2-F3 fibrosis	MASH regression 62.9% (placebo 34.3%); fibrosis regression 36.8% (placebo 22.4%); mean weight loss 10.5%

Two Important Limits: Both drugs are approved only for noncirrhotic patients with F2-F3 fibrosis —not for early steatosis or cirrhosis. The American liver society’s November 2025 update does not require biopsy for semaglutide, accepting F2-F3 fibrosis established by noninvasive tests, but cirrhosis must be excluded. There are no data on using the two drugs together. Tirzepatide produced impressive phase 2 results (MASH regression up to 62%), but for this indication it is not approved.

The Situation in Turkey: No record of resmetirom licensing in Turkey was found (September 2026). Semaglutide is available in Turkey, licensed for obesity/diabetes rather than MASH. FibroScan is available at university and training/research hospitals and many private centers, but SGK reimbursement could not be verified.

An Important Correction About Statins. For years, the teaching was “stop statins if liver enzymes rise.” This view has changed.

In February 2012, the FDA removed mandatory routine liver enzyme monitoring from statin labels: test once at baseline, then only when clinically indicated.
The American liver society’s 2023 guidance is clear: “Statins are safe and recommended to reduce cardiovascular risk throughout fatty liver disease, including compensated cirrhosis.” European guidance agrees.
The reason matters: Cardiovascular disease, not liver disease, is the leading cause of death in MASLD. Stopping a statin for mildly elevated enzymes leaves the patient unprotected against the main risk.
Caution is needed in decompensated cirrhosis.

A Disagreement: Vitamin E and Pioglitazone. The American guideline offers nondiabetic patients with biopsy-proven MASH vitamin E 800 IU/day as an option, not routine practice, and considers pioglitazone with coexisting diabetes. European guidance rejects both, citing insufficient phase 3 evidence. This is a real disagreement and should not be merged into one recommendation.

How Long Until Levels Normalize?

Situation	Expected time
Medication- or supplement-related	After stopping the responsible product, weeks; weeks to months in severe cases
Alcohol	After stopping alcohol, a marked fall in GGT within 3-4 weeks ; transaminases within 1-2 months
MASLD/MASH	With diet and exercise, meaningful improvement within 3-6 months .
Acute viral hepatitis	Weeks to months
Chronic viral hepatitis	Months with antiviral treatment; fluctuations possible
Cholestasis of pregnancy	Usually after delivery, within a few weeks
Exercise-related	7-12 days

As a general rule, repeat testing after 2-4 weeks . If elevation persists for more than six months and remains unexplained, further investigation is needed.

When Is It an Emergency?

The Height of the Enzyme Level Does Not Determine Severity. This is the article’s most important clinical message. An alert patient with ALT 3,000 and normal INR is much safer than one with ALT 600 but INR 2.2 and confusion . Three criteria determine severity: INR (clotting), bilirubin and mental status.

Findings Requiring Same-Day Assessment:

Jaundice, dark urine, pale stools
Confusion, excessive sleepiness, reversed sleep pattern, flapping hand tremor (hepatic encephalopathy)
Prolonged INR/prothrombin time
Severe upper-right abdominal pain + fever + low blood pressure (cholangitis or ischemic hepatitis)
AST/ALT above 10 times normal, especially 15 times normal
Suspected ingestion of any amount of paracetamol .
New abdominal fluid, bleeding, easy bruising

Hy’s Law: In a patient taking a medication, ALT above 3 times normal and total bilirubin above 2 times normal, without marked ALP elevation, indicate serious drug-induced liver injury and approximately 10% risk of death/transplantation. The drug should be stopped immediately and the patient referred.

Frequently Asked Questions

My Enzymes Are Slightly High. Should I Worry?: Mild elevation is very common and does not itself mean serious disease. The correct first step is repeating the test after at least a week without heavy exercise. If persistent, review metabolic risks (weight, blood glucose, blood pressure, triglycerides), alcohol, medications and supplements, and test for viral hepatitis.
The Laboratory Says “Normal,” but You Give a Different Threshold. Which Is Right?: Both. The laboratory range reflects people tested there, including many with fatty liver. The healthy upper limit is established separately: 29-33 in men and 19-25 U/L in women. In someone with metabolic risk factors, ALT above this threshold merits assessment even if the laboratory calls it “normal.”
Only My GGT Is High. Is My Liver Damaged?: Probably not. Isolated GGT elevation is common and associated with alcohol, certain medications and fatty liver. Guidelines advise against using GGT for screening when other tests are normal. Nonprogressive isolated elevation rarely indicates serious disease.
Should I Stop My Statin When Liver Enzymes Are High?: No—do not stop it yourself. Current guidelines describe statins as safe and recommended in fatty liver disease. In 2012, the FDA removed mandatory routine enzyme monitoring. Cardiovascular disease is the leading cause of death in fatty liver; unnecessary statin discontinuation increases the main risk. Your doctor decides.
Do Liver Detoxes, Milk Thistle or Turmeric Work?: No product “cleanses” the liver: it is already the body’s cleansing organ. More importantly, some herbal products cause liver injury themselves. US data attribute more than 20% of drug-induced liver injury to herbal/dietary supplements, including turmeric/curcumin, concentrated green tea extract, ashwagandha and Garcinia.
Why Test for Hepatitis B Before Chemotherapy?: Immunosuppressive treatments can reactivate hepatitis B acquired years earlier and now dormant. One in three adults in Turkey has encountered hepatitis B. HBsAg testing alone is insufficient; also test anti-HBc for previous infection. If needed, preventive antiviral treatment is started and continued at least 12 months after cancer treatment, or 2 years after rituximab.
I Have Cancer and Elevated Enzymes. Does That Mean Metastasis?: Not necessarily. Causes also include chemotherapy itself, targeted drugs, immunotherapy hepatitis, infections and supportive medications. However, a pattern dominated by marked ALP and GGT elevation requires imaging for liver metastases.
I Have Fatty Liver. Do I Need Medication?: Most patients do not. Drugs (resmetirom or semaglutide) are approved only for noncirrhotic patients with moderate-to-advanced fibrosis (F2-F3) , identified using noninvasive tests (FIB-4, elastography). For others, treatment remains weight loss, diet and exercise . These are not weak measures but the strongest interventions: 10% weight loss can reverse fibrosis.
Why Can Enzymes Be Normal in Cirrhosis?: Because AST and ALT are enzymes leaking from injured cells . Advanced cirrhosis leaves fewer functional cells available for injury, reducing enzyme release. The liver’s true condition is then assessed through albumin, bilirubin and INR . “My enzymes are normal, so my liver is fine” is therefore not always true.
Must I Stop Alcohol Completely?: Yes, while the elevation is being investigated and until its cause is known. Under the new classification, intake above 210 g weekly for men or 140 g for women changes the disease’s name and course. If liver disease is diagnosed, any decision to resume alcohol should be made with a doctor.

Glossary

Transaminase: Collective name for AST and ALT; indicates liver cell injury.
Cholestasis: Slowed or blocked bile flow, with elevated ALP and GGT.
Steatosis: Fat accumulation in the liver.
Steatohepatitis: Fat accompanied by inflammation and cell injury. This stage can progress to fibrosis.
Fibrosis: Accumulation of scar tissue in the liver, graded F0 to F4; F4 is cirrhosis.
MASLD/MASH: Metabolic dysfunction-associated fatty liver disease and its inflammatory form. Replaced NAFLD and NASH in 2023.
FIB-4: Free score calculated from age, AST, ALT and platelet count to estimate advanced fibrosis likelihood.
Elastography (FibroScan): A painless method measuring liver stiffness using sound waves.
INR: Clotting time; one of the indicators of actual liver function.
Hy’s law: A laboratory pattern warning of serious drug-induced liver injury.
HBV reactivation: Renewed replication of dormant hepatitis B virus during immunosuppression.

DROZDOGAN Academy Commentary

Elevated liver enzymes are among the most common outpatient “what should I do?” questions. Here is our perspective.

⚡ Why Does This Matter?

Because two opposite mistakes occur simultaneously. On one hand, there is unnecessary alarm : a healthy young person with ALT 48 undergoes repeated investigations and even biopsy. On the other, there is unnecessary reassurance : an overweight, prediabetic patient with ALT 45-50 for years receives no assessment because “the laboratory says normal.” The second mistake is more common and costly, because MASLD progresses silently and may present as cirrhosis.

✅ What Has Really Improved Recently?

Three things have changed, all positively. First, diagnosis no longer depends on biopsy: a free score such as FIB-4 and elastography classify most patients accurately. Second, effective drugs exist for the first time: resmetirom and semaglutide can, compared with placebo, produce fibrosis regression—a goal that seemed out of reach a decade ago. Third, the terminology change is not cosmetic: MASLD is now a diagnosis based on positive criteria, not exclusion , and MetALD finally makes visible a large group who say, “I drink only a little, but I do drink.”

⚠️ What Should Not Be Overstated?

The new drugs have accelerated approval based on histological endpoints: “improvement on biopsy” has been shown, but fewer cases of cirrhosis or liver cancer and longer survival have not yet been demonstrated. Clinical outcome data in cirrhosis (MAESTRO-NASH OUTCOMES) are still awaited. Both drugs are also approved only for a narrow F2-F3 group ; most patients fall outside this definition, and lifestyle remains their treatment. No record of resmetirom licensing in Turkey has been found.

Furthermore: American and European guidelines clearly disagree on vitamin E and pioglitazone. In this situation, “the guidelines recommend” depends on which guideline one reads. Honesty requires reporting the disagreement as it stands.

🩺 Our Practical Approach

1. Do not start investigating on the basis of a single high value. Repeat testing after at least a week without heavy exercise. If not persistent, that is often the end of the matter.

2. With persistent elevation, first ask for the medication and supplement list. Most patients do not spontaneously mention herbal products; ask.

3. Calculate FIB-4. There is no additional cost: it uses four already available values. This step largely determines who needs a hepatologist.

4. Look at the patient’s metabolic profile, not the laboratory’s “normal” label. Someone with ALT 40, a large waist and HbA1c 5.9 is not “normal,” but a person needing investigation .

5. The Highest-Yield Step in Oncology: Before chemotherapy, request HBsAg + anti-HBc + anti-HBs together. In Turkey, where one in three adults has encountered the virus, HBsAg alone is insufficient. This single request may prevent avoidable liver failure.

6. Do not stop statins because of elevated enzymes. This established but now incorrect reflex leaves patients unprotected against the main risk: cardiovascular disease.

❓ Open Questions

Will resmetirom and semaglutide translate histological improvement into actual clinical outcomes (cirrhosis, liver cancer, death)? Will using them together add benefit? There are currently no data. Will an effective treatment emerge for cirrhotic MASH? In Turkey, will these drugs become accessible, and under what reimbursement conditions? Finally, will the infliximab prohibition in immunotherapy hepatitis be lifted? Data from 2024-2025 raise questions.

Our Brief Verdict: Elevated liver enzymes are not a disease but a question. The right approach is neither panic nor neglect: repeat, examine the pattern, calculate FIB-4, and ask about medications/supplements. These four steps prevent much unnecessary investigation and missed cirrhosis simultaneously. For oncology patients, add a fifth, most urgent step: screen for hepatitis B before treatment.

Transparency Note. (1) Whether resmetirom is licensed in Turkey could not be verified; finding no record does not establish that it is unlicensed. (2) SGK reimbursement for FibroScan and hepatitis B screening before chemotherapy could not be verified directly from the SUT text. (3) MAESTRO-NASH OUTCOMES results (clinical endpoints in cirrhosis) have not yet been published. (4) Histological benefits associated with weight-loss percentages come from guidelines; numerical data from the original 2015 study underlying these thresholds could not be verified from the primary source. (5) Trastuzumab deruxtecan hepatotoxicity frequency could not be verified, so no numerical value is given. (6) No reliable rate for macro-AST frequency was found in the literature. (7) No reliable pooled data were found for overall liver-test abnormality frequency in cancer patients. (8) The commonly cited daily paracetamol limit in cirrhosis is not guideline evidence but expert opinion. (9) Full ESMO and SITC immunotherapy hepatitis guidelines were inaccessible; management recommendations are based on ASCO 2021 and NCCN.

This Article Is for Information and does not replace personal medical advice. Causes of elevated liver enzymes are determined through history, examination, laboratory tests and imaging together. Do not stop or start any medication without consulting your doctor.

References

Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology / J Hepatol / Ann Hepatol, online June 24, 2023.
Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112:18-35.
EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD. J Hepatol 2024.
AASLD Practice Guidance on the clinical assessment and management of NAFLD/MASLD, 2023; semaglutide update Hepatology, November 2025.
Harrison SA, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). N Engl J Med 2024.
Sanyal AJ, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med 2025.
Loomba R, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med 2024.
Hwang JP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020;38:3698-3715.
Türkiye Hepatit B Tanı ve Tedavi Kılavuzu 2023; Türkiye Hepatit C Tanı ve Tedavi Kılavuzu 2023. Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği / Viral Hepatitle Savaşım Derneği.
Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39:4073-4126.
NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities.
Vauthey JN, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-72.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Oxaliplatin, lapatinib and paracetamol monographs. NIH/NIDDK.
DAHUDER MASLD Study: nationwide multicenter study in Türkiye. J Clin Med 2025;14:7098.
Likhitsup A, et al. Estimated exposure to six potentially hepatotoxic botanicals in US adults. JAMA Netw Open 2024.
FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs, February 2012.
AASLD Practice Guidance on prevention, diagnosis and treatment of hepatocellular carcinoma, 2023; AGA Clinical Practice Update on HCC surveillance, 2026.
Bayraktar V, Coşar AM. Karaciğer Enzim Yüksekliklerine Yaklaşım. Güncel Gastroenteroloji 2019;23(1).

Sources

1. Agrawal, S., et al. (2022). Acetaminophen toxicity. https://www.ncbi.nlm.nih.gov/books/NBK441917/

2. Common liver tests. (2019). https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/common-liver-tests

3. Heath, R. D., et al. (2017). Coffee: The magical bean for liver diseases. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440772/

4. Malakouti, M., et al. (2017). Elevated liver enzymes in asymptomatic patients – what should I do? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719197/

5. Munsterman., I. D., et al. (2018). Biochemical effects on the liver of 1 month of alcohol abstinence in moderate alcohol consumers. https://academic.oup.com/alcalc/article/53/4/435/4992161

6. Oh, R. C., et al. (2017). Mildly elevated liver transaminase levels: causes and evaluation. https://www.aafp.org/afp/2017/1201/p709.html

7. Salomone, F., et al. (2017). Molecular bases underlying the hepatoprotective effects of coffee. Nutrients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295129/

8. Shamsoddini, A., et al. (2015). Effect of aerobic and resistance exercise training on liver enzymes and hepatic fat in Iranian men with nonalcoholic fatty liver disease. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644631

9. Smoking and liver disease – gastroenterology & hepatology. (2020). https://www.gastroenterologyandhepatology.net/archives/december-2020/smoking-and-liver-disease/

10. Wen-Xing, Li, et al. (2016). Folate Deficiency Was Associated with Increased Alanine Aminotransferase and Glutamyl Transpeptidase Concentrations in a Chinese Hypertensive Population: A Cross-Sectional Study https://www.jstage.jst.go.jp/article/jnsv/62/4/62_265/_pdf

Reader comments

Share your comment

Your name and comment are published only after administrator approval. Your email address is never shown to visitors.

Be the first to comment.

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

Menu

What Are Liver Enzymes? Symptoms, Causes and Treatment of Elevated Levels

My Liver Enzymes Are High: What Does That Mean?

What Does Each Enzyme Show?